Amphotericin B. Still the 'gold standard' for antifungal therapy.

Amphotericin B (Fungizone) remains the cornerstone of antifungal therapy because of its broad-spectrum fungicidal activity and rapid onset of action. Ketoconazole (Nizoral) and the new triazoles are welcome additions to the therapeutic armamentarium but do not replace amphotericin B. Adverse side effects of amphotericin B treatment are usually manageable and often preventable. Careful attention to detail reduces immediate toxicity and allows completion of the desired therapeutic course without an undue risk of permanent nephrotoxicity.

[1]  Zeluff Bj.  Fungal pneumonia in transplant recipients. , 1990 .

[2]  D. Smith,et al.  Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). , 1989, Annals of internal medicine.

[3]  S. Chuck,et al.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. , 1989, The New England journal of medicine.

[4]  G. Sarosi,et al.  Clinical review: progressive disseminated histoplasmosis in the AIDS patient. , 1989, Seminars in respiratory infections.

[5]  G. Sarosi,et al.  Chronic cavitary histoplasmosis. Failure of oral treatment with ketoconazole. , 1989, Chest.

[6]  J. Galgiani,et al.  Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis. , 1988, Infectious disease clinics of North America.

[7]  J. Graybill.  Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. , 1988, Infectious disease clinics of North America.

[8]  R. Branch,et al.  Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. , 1988, Archives of internal medicine.

[9]  A. Sugar,et al.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. , 1988, The American journal of medicine.

[10]  A. Zuger,et al.  Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[11]  C. Fletcher,et al.  Effect of Infusion Rate on Amphotericin B-Associated Febrile Reactions , 1988, Drug intelligence & clinical pharmacy.

[12]  W. Dismukes.  Cryptococcal meningitis in patients with AIDS. , 1988, The Journal of infectious diseases.

[13]  J. Galgiani,et al.  Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. , 1988, The American journal of medicine.

[14]  R. Diasio,et al.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. , 1987, The New England journal of medicine.

[15]  G. Medoff.  Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. , 1987, Reviews of infectious diseases.

[16]  J. Galgiani,et al.  Coccidioidomycosis in the acquired immunodeficiency syndrome. , 1987, Annals of internal medicine.

[17]  E. Labadie,et al.  Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. , 1986, Archives of internal medicine.

[18]  Gerding Dn.  Treatment of pulmonary sporotrichosis. , 1986 .

[19]  D. Gremillion,et al.  Risk factors of ventricular fibrillation during rapid amphotericin B infusion , 1985, Antimicrobial Agents and Chemotherapy.

[20]  G. Rankin,et al.  Nephrotoxicity of antifungal agents. , 1985, Adverse drug reactions and acute poisoning reviews.

[21]  N. Vaziri,et al.  Renal magnesium wasting associated with amphotericin B therapy. , 1984, The American journal of medicine.

[22]  Á. Restrepo,et al.  Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience. , 1983, The American journal of medicine.

[23]  R. Sobel,et al.  Leukoencephalopathy in patients treated with amphotericin B methyl ester. , 1982, The Journal of infectious diseases.

[24]  J. Fierer,et al.  Ketoconazole for treatment of disseminated coccidioidomycosis. , 1982, Annals of internal medicine.

[25]  C. Tuazon,et al.  Amphotericin-B-induced thrombocytopenia. , 1982, Annals of internal medicine.

[26]  G. Sarosi,et al.  Chronic blastomycotic meningitis. , 1981, The American journal of medicine.

[27]  P. Pizzo,et al.  Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. , 1981, The New England journal of medicine.

[28]  R. Duma,et al.  The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. , 1981, Annals of internal medicine.

[29]  R. F. White,et al.  Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. , 1981, Blood.

[30]  R. Branch,et al.  The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. , 1980, The Journal of pharmacology and experimental therapeutics.

[31]  J. Pennington.  Aspergillus lung disease. , 1980, The Medical clinics of North America.

[32]  J. Aisner,et al.  Meperidine for the treatment of shaking chills and fever. , 1980, Archives of internal medicine.

[33]  G. Medoff,et al.  Strategies in the treatment of systemic fungal infections. , 1980, The New England journal of medicine.

[34]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[35]  G. Sarosi,et al.  Disseminated histoplasmosis: results of long-term follow-up. A center for disease control cooperative mycoses study. , 1971, Annals of internal medicine.

[36]  G. Sarosi,et al.  Treatment of chronic pulmonary histoplasmosis. , 1970, Maryland state medical journal.

[37]  D. Drutz,et al.  Hypokalemic rhabdomyolysis and myoglobinuria following amphotericin B therapy. , 1970, JAMA.

[38]  J. Bennett,et al.  A pharmacologic guide to the clinical use of amphotericin B. , 1969, The Journal of infectious diseases.

[39]  W. Winn.  A long term study of 300 patients with cavitary-abscess lesions of the lung of coccidioidal origin. An analytical study with special reference to treatment. , 1968, Diseases of the chest.

[40]  D. E. Rogers,et al.  Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. , 1968, The American journal of medicine.

[41]  J. Bennett,et al.  Amphotericin B Toxicity: Combined Clinical Staff Conference at the National Institutes of Health , 1964 .

[42]  D. Alling,et al.  Reducing amphotericin B reactions. A double-blind study. , 1963, The American review of respiratory disease.

[43]  L. Hyde.  Coccidioidal pulmonary cavitation. , 1968, Diseases of the chest.

[44]  R. Donovick,et al.  Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. , 1955, Antibiotics annual.